| Literature DB >> 34367002 |
Svenja Heyne1, Peter Esser1, Kristina Geue1, Michael Friedrich1, Anja Mehnert-Theuerkauf1.
Abstract
BACKGROUND: Multimodal cancer treatments are often associated with sexual problems. Identifying patients with sexual problems could help further elucidate serious issues with their sexuality and thus promote or maintain patients' sexual health. We aimed to assess the occurrence of sexual problems in patients across different tumor locations and to explore associated sociodemographic, medical and psychosocial factors.Entities:
Keywords: anxiety; cancer; distress; epidemiology; oncology; quality of life; screening; sexual problems
Year: 2021 PMID: 34367002 PMCID: PMC8339199 DOI: 10.3389/fpsyg.2021.679870
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Sociodemographic and medical factors of cancer patients stating sexual problems compared with total sample.
| Total sample | Sexual problems “Yes” | |
| 3,677 (100.0) | 1,170 (31.8) | |
| Male | 1,787 | 723 (40.5) |
| Female | 1,890 | 447 (23.7) |
| 18–35 | 150 | 37 (24.7) |
| 36–45 | 376 | 110 (29.3) |
| 46–55 | 839 | 283 (33.7) |
| 56–65 | 1140 | 380 (33.3) |
| 66–75 | 1119 | 340 (30.4) |
| Single | 442 | 100 (22.6) |
| Married | 2,554 | 904 (35.4) |
| Divorced | 382 | 100 (26.2) |
| Widowed | 217 | 38 (17.5) |
| Yes | 2,794 | 994 (35.6) |
| No | 655 | 23 (3.5) |
| Employed | 1,479 | 458 (31.0) |
| Unemployed | 203 | 67 (33.0) |
| Retired | 1,642 | 548 (33.4) |
| Other | 215 | 54 (25.1) |
| Breast | 840 | 210 (25.0) |
| Digestive organs | 725 | 189 (26.1) |
| Male genital organs | 630 | 363 (57.6) |
| Prostate | 592 | 352 (59.5) |
| Testicles | 34 | 11 (32.4) |
| Penis | 4 | 0 (0.0) |
| Respiratory organs | 303 | 84 (27.7) |
| Female genital organs | 294 | 85 (28.9) |
| Ovar | 115 | 31 (27.0) |
| Uterus | 66 | 39 (59.1) |
| Vulva | 29 | 10 (34.5) |
| Vagina | 6 | 4 (66.7) |
| Hematological cancers | 277 | 69 (24.9) |
| Urinary tract | 199 | 61 (30.7) |
| Lip, oral cavity and pharynx | 101 | 34 (33.7) |
| Skin | 79 | 22 (27.9) |
| CNS (eye, brain, other parts) | 66 | 19 (28.8) |
| Mesothelial and soft tissue | 57 | 13 (22.8) |
| other | 106 | 26 (24.5) |
| Inpatient care | 1,536 | 453 (29.5) |
| Outpatient care | 1,228 | 413 (33.6) |
| Inpatient rehabilitation | 913 | 304 (33.3) |
| I | 547 | 154 (28.2) |
| II | 643 | 236 (36.7) |
| III | 505 | 170 (33.7) |
| IV | 787 | 252 (32.0) |
| Uncertain | 1,142 | 337 (29.5) |
Means, standard deviations, and effect sizes.
| Sexual problems | |||||
| “Yes” | “No” | ||||
| Variable | η2 | ||||
| 1,104 | 2,333 | ||||
| Symptoms of depression | 7.47 (4.94) | 5.81 (4.33) | 0.028 | ||
| Symptoms of anxiety | 6.49 (4.36) | 4.52 (3.71) | 0.052 | ||
| Symptoms of distress | 5.15 (2.55) | 4.26 (2.53) | 0.026 | ||
| Positive support | 13.37 (2.90) | 13.80 (2.70) | 0.005 | ||
| Detrimental interaction | 4.06 (3.10) | 3.48 (3.11) | 0.008 | ||
| Physical functioning | 67.52 (23.68) | 72.43 (23.18) | 0.010 | ||
| Roles functioning | 49.46 (34.43) | 59.81 (34.56) | 0.019 | ||
| Cognitive functioning | 68.30 (28.65) | 79.30 (24.91) | 0.037 | ||
| Social functioning | 50.51 (33.27) | 66.19 (31.84) | 0.049 | ||
| Emotional functioning | 56.04 (26.80) | 69.03 (24.54) | 0.054 | ||
| Global health | 50.82 (22.62) | 58.96 (22.52) | 0.028 | ||
Multivariate hierarchical logistic regression of sexual problems with sociodemographic and psychosocial factors as determinants.
| Model 1 | ( | Model 2 | ( | Model 3 | ( | Model 4 | ( | Model 5 | ( | Model 6 | ( | |
| OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | OR | 95% CI | |
| Sexa | 2.03* | 1.73–2.38 | 2.61* | 2.19–3.10 | 2.61* | 2.20–3.11 | 2.71* | 2.27–3.25 | 2.37* | 1.82–3.10 | 2.35* | 1.80–3.07 |
| Ageb | 0.96 | 0.89–1.03 | 1.03 | 0.95–1.11 | 1.03 | 0.95–1.11 | 1.06 | 0.98–1.15 | 0.99 | 0.91–1.10 | 0.99 | 0.91–1.08 |
| Living with a partnerc | 2.16* | 1.72–2.70 | 2.54* | 2.00–3.22 | 3.04* | 2.35–3.92 | 2.82* | 2.18–3.65 | 2.82* | 2.16–3.67 | 2.83* | 2.17–3.70 |
| Distressd | 1.05* | 1.01–1.09 | 1.05* | 1.01–1.09 | 1.02 | 0.98–1.06 | 1.02 | 0.98–1.07 | 1.02 | 0.98–1.07 | ||
| Depressive symptomse | 1.04* | 1.02–1.07 | 1.04* | 1.02–1.06 | 1.01 | 0.98–1.03 | 1.02 | 0.99–1.05 | 1.02 | 0.99–1.05 | ||
| Symptoms of anxietyf | 1.11* | 1.08–1.14 | 1.10* | 1.08–1.13 | 1.06* | 1.02–1.09 | 1.05* | 1.02–1.09 | 1.05* | 1.02–1.10 | ||
| Positive supportg | 0.93* | 0.90–0.96 | 0.94* | 0.91–0.97 | 0.93* | 0.90–0.97 | 0.93* | 0.90–0.97 | ||||
| Detrimental interactionh | 1.01 | 0.98–1.04 | 1.00 | 0.97–1.03 | 1.01 | 0.98–1.04 | 1.01 | 0.98–1.04 | ||||
| Global healthi | 1.00 | 0.99–1.01 | 1.00 | 0.99–1.00 | 1.00 | 0.99–1.00 | ||||||
| Physical functioningj | 1.00 | 0.98–1.01 | 1.00 | 0.99–1.01 | 1.00 | 1.00–1.01 | ||||||
| Emotional functioningk | 0.99* | 0.98–0.99 | 0.99* | 0.99–1.00 | 0.99* | 0.99–1.00 | ||||||
| Social functioningl | 0.99* | 0.98–0.99 | 0.99* | 0.99–1.00 | 0.99* | 0.99–1.00 | ||||||
| Roles functioningm | 0.99 | 0.99–1.99 | 1.00 | 0.99–1.00 | 1.00 | 1.00–1.01 | ||||||
| Cognitive functioningo | 0.99* | 0.98–0.99 | 0.99* | 0.99–1.00 | 0.99* | 0.99–1.00 | ||||||
| Digestive organs | 0.60* | 0.44–0.83 | 0.60* | 0.42–0.85 | ||||||||
| Male genital organs | 2.46* | 1.71–3.55 | 2.65* | 1.78–3.95 | ||||||||
| Respiratory organs | 0.61* | 0.41–0.91 | 0.57* | 0.37–0.87 | ||||||||
| Female genital organs | 1.16 | 0.82–1.64 | 1.15 | 0.80–1.66 | ||||||||
| Blood and blood-forming organs | 0.46* | 0.30–0.68 | 0.43* | 0.27–0.68 | ||||||||
| Urinary tract | 0.74 | 0.48–1.16 | 0.81 | 0.50–1.30 | ||||||||
| Lip, oral cavity and pharynx | 0.84 | 0.48–1.44 | 0.76 | 0.43–1.33 | ||||||||
| Skin | 0.57 | 0.30–1.07 | 0.59 | 0.31–1.14 | ||||||||
| Eye. Brain, other parts of CNS | 0.78 | 0.41–1.49 | 0.73 | 0.37–1.41 | ||||||||
| Mesothelial and soft tissues | 0.36* | 0.17–0.79 | 0.36* | 0.16–0.79 | ||||||||
| Operation | 0.91 | 0.72–1.15 | ||||||||||
| Radiation therapy | 1.17 | 0.97–1.41 | ||||||||||
| Chemotherapy | 1.10 | 0.90–1.35 | ||||||||||
| Hormontherapy | 0.87 | 0.66–1.15 | ||||||||||